Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes].

    Abstract

    The sodium-glucose cotransporter 2 inhibitor (SGLT-2i)-class is efficacious as monotherapy and as add-on therapy with an expected lowering of the glycated haemoglobin (HbA1c) concentration of approximately 7 mmol/mol. Side effects relate to the mode of action, genital infections are the main problem. Extremely rare cases of ketoacidosis are reported, mostly in patients with Type 1 diabetes. One SGLT-2i, empagliflozin, has been shown to reduce cardiovascular mortality and progression of kidney disease in patients with Type 2 diabetes and cardiovascular disease. Outcome trials for other SGLT-2i are pending. SGLT-2i are now in guidelines as a possible second-line therapy or in case of metformin intolerance.

    OriginalsprogEngelsk
    TidsskriftUgeskrift for Laeger
    Vol/bind178
    Udgave nummer38
    ISSN0041-5782
    StatusUdgivet - 19 sep. 2016

    Fingeraftryk

    Dyk ned i forskningsemnerne om 'Sodium-glucose cotransporter 2 (SGLT-2) inhibitors for patients with Type 2 diabetes].'. Sammen danner de et unikt fingeraftryk.

    Citationsformater